Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

已完结 10 由 ! 发布于 2025/2/4 21:09:48

DOI:10.1056/NEJMoa2407086
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1056/NEJMoa2407086

New England Journal of Medicine (NEJM)

Abstract：Background: Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy

应助信息

8小时前

heqiang

e8ea4e8be2fa11efa7a334735aa3bc31.zip 已采纳

8小时前

Book学术机器人

2025/2/4 21:09:48 未找到该文献，机器人已退出，请等待人工下载

2025/2/4 21:09:48 Book学术AI机器人收到请求，开始寻找文献

2025/2/4 21:09:48 已向机器人发送请求

8小时前

! 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Society of Clinical Oncology (ASCO)Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breas